Top Markets
Coin of the day
GSK plc GSK plc

GSK plc

GSK
Rank in Stocks #199
GSK plc, together with its subsidiaries, engages in the creation, discovery,... GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Share Price
$51.99
Market Cap
$104.42B
Change (1 day)
0.29%
Change (1 year)
32.49%
Country
GB
Trade GSK plc (GSK)

Category

P/E ratio for GSK plc (GSK)
P/E ratio as of March 2026 TTM: 14.28
According to GSK plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.28. At the end of 2024 the company had a P/E ratio of 21.32.
P/E ratio history for GSK plc from 2000 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 14.28 10.44%
2025 12.93 -39.35%
2024 21.32 78.79%
2023 11.92 208.12%
2022 3.87 -67.35%
2021 11.85 26.27%
2020 9.39 -38.69%
2019 15.31 -6.32%
2018 16.34 -52.05%
2017 34.08 -49.33%
2016 67.26 956.89%
2015 6.36 -67.19%
2014 19.40 67.62%
2013 11.57 -1.74%
2012 11.78 3.64%
2011 11.36 -63.56%
2010 31.18 219.11%
2009 9.77 -16.60%
2008 11.72 7.01%
2007 10.95 -5.13%
2006 11.54 -19.65%
2005 14.36 -0.89%
2004 14.49 8.99%
2003 13.30 -8.11%
2002 14.47 -46.94%
2001 27.27 22.42%
2000 22.28 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
42.86 200.15%
US
28.47 99.34%
GB
21.88 53.24%
US
92.55 548.10%
US
20.85 46.00%
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.